Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer : A National COVID Cancer Cross-sectional Evaluation
Importance: Accurate identification of patient groups with the lowest level of protection following COVID-19 vaccination is important to better target resources and interventions for the most vulnerable populations. It is not known whether SARS-CoV-2 antibody testing has clinical utility for high-risk groups, such as people with cancer.
Objective: To evaluate whether spike protein antibody vaccine response (COV-S) following COVID-19 vaccination is associated with the risk of SARS-CoV-2 breakthrough infection or hospitalization among patients with cancer.
Design, Setting, and Participants: This was a population-based cross-sectional study of patients with cancer from the UK as part of the National COVID Cancer Antibody Survey. Adults with a known or reported cancer diagnosis who had completed their primary SARS-CoV-2 vaccination schedule were included. This analysis ran from September 1, 2021, to March 4, 2022, a period covering the expansion of the UK's third-dose vaccination booster program.
Interventions: Anti-SARS-CoV-2 COV-S antibody test (Elecsys; Roche).
Main Outcomes and Measures: Odds of SARS-CoV-2 breakthrough infection and COVID-19 hospitalization.
Results: The evaluation comprised 4249 antibody test results from 3555 patients with cancer and 294 230 test results from 225 272 individuals in the noncancer population. The overall cohort of 228 827 individuals (patients with cancer and the noncancer population) comprised 298 479 antibody tests. The median age of the cohort was in the age band of 40 and 49 years and included 182 741 test results (61.22%) from women and 115 737 (38.78%) from men. There were 279 721 tests (93.72%) taken by individuals identifying as White or White British. Patients with cancer were more likely to have undetectable anti-S antibody responses than the general population (199 of 4249 test results [4.68%] vs 376 of 294 230 [0.13%]; P < .001). Patients with leukemia or lymphoma had the lowest antibody titers. In the cancer cohort, following multivariable correction, patients who had an undetectable antibody response were at much greater risk for SARS-CoV-2 breakthrough infection (odds ratio [OR], 3.05; 95% CI, 1.96-4.72; P < .001) and SARS-CoV-2-related hospitalization (OR, 6.48; 95% CI, 3.31-12.67; P < .001) than individuals who had a positive antibody response.
Conclusions and Relevance: The findings of this cross-sectional study suggest that COV-S antibody testing allows the identification of patients with cancer who have the lowest level of antibody-derived protection from COVID-19. This study supports larger evaluations of SARS-CoV-2 antibody testing. Prevention of SARS-CoV-2 transmission to patients with cancer should be prioritized to minimize impact on cancer treatments and maximize quality of life for individuals with cancer during the ongoing pandemic.
| Errataetall: |
CommentIn: JAMA Oncol. 2023 Feb 1;9(2):177-179. - PMID 36547943 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
JAMA oncology - 9(2023), 2 vom: 01. Feb., Seite 188-196 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lee, Lennard Y W [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 22.02.2023 Date Revised 01.03.2024 published: Print CommentIn: JAMA Oncol. 2023 Feb 1;9(2):177-179. - PMID 36547943 Citation Status MEDLINE |
|---|
| doi: |
10.1001/jamaoncol.2022.5974 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35059516X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35059516X | ||
| 003 | DE-627 | ||
| 005 | 20240301231922.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1001/jamaoncol.2022.5974 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1313.xml |
| 035 | |a (DE-627)NLM35059516X | ||
| 035 | |a (NLM)36547970 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lee, Lennard Y W |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer |b A National COVID Cancer Cross-sectional Evaluation |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.02.2023 | ||
| 500 | |a Date Revised 01.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: JAMA Oncol. 2023 Feb 1;9(2):177-179. - PMID 36547943 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Importance: Accurate identification of patient groups with the lowest level of protection following COVID-19 vaccination is important to better target resources and interventions for the most vulnerable populations. It is not known whether SARS-CoV-2 antibody testing has clinical utility for high-risk groups, such as people with cancer | ||
| 520 | |a Objective: To evaluate whether spike protein antibody vaccine response (COV-S) following COVID-19 vaccination is associated with the risk of SARS-CoV-2 breakthrough infection or hospitalization among patients with cancer | ||
| 520 | |a Design, Setting, and Participants: This was a population-based cross-sectional study of patients with cancer from the UK as part of the National COVID Cancer Antibody Survey. Adults with a known or reported cancer diagnosis who had completed their primary SARS-CoV-2 vaccination schedule were included. This analysis ran from September 1, 2021, to March 4, 2022, a period covering the expansion of the UK's third-dose vaccination booster program | ||
| 520 | |a Interventions: Anti-SARS-CoV-2 COV-S antibody test (Elecsys; Roche) | ||
| 520 | |a Main Outcomes and Measures: Odds of SARS-CoV-2 breakthrough infection and COVID-19 hospitalization | ||
| 520 | |a Results: The evaluation comprised 4249 antibody test results from 3555 patients with cancer and 294 230 test results from 225 272 individuals in the noncancer population. The overall cohort of 228 827 individuals (patients with cancer and the noncancer population) comprised 298 479 antibody tests. The median age of the cohort was in the age band of 40 and 49 years and included 182 741 test results (61.22%) from women and 115 737 (38.78%) from men. There were 279 721 tests (93.72%) taken by individuals identifying as White or White British. Patients with cancer were more likely to have undetectable anti-S antibody responses than the general population (199 of 4249 test results [4.68%] vs 376 of 294 230 [0.13%]; P < .001). Patients with leukemia or lymphoma had the lowest antibody titers. In the cancer cohort, following multivariable correction, patients who had an undetectable antibody response were at much greater risk for SARS-CoV-2 breakthrough infection (odds ratio [OR], 3.05; 95% CI, 1.96-4.72; P < .001) and SARS-CoV-2-related hospitalization (OR, 6.48; 95% CI, 3.31-12.67; P < .001) than individuals who had a positive antibody response | ||
| 520 | |a Conclusions and Relevance: The findings of this cross-sectional study suggest that COV-S antibody testing allows the identification of patients with cancer who have the lowest level of antibody-derived protection from COVID-19. This study supports larger evaluations of SARS-CoV-2 antibody testing. Prevention of SARS-CoV-2 transmission to patients with cancer should be prioritized to minimize impact on cancer treatments and maximize quality of life for individuals with cancer during the ongoing pandemic | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Tilby, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Starkey, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Ionescu, Maria C |e verfasserin |4 aut | |
| 700 | 1 | |a Burnett, Alex |e verfasserin |4 aut | |
| 700 | 1 | |a Hattersley, Rosie |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Sam |e verfasserin |4 aut | |
| 700 | 1 | |a Little, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Justin K H |e verfasserin |4 aut | |
| 700 | 1 | |a Platt, James R |e verfasserin |4 aut | |
| 700 | 1 | |a Tripathy, Arvind |e verfasserin |4 aut | |
| 700 | 1 | |a Watts, Isabella |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, Sophie Therese |e verfasserin |4 aut | |
| 700 | 1 | |a Appanna, Nathan |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Hajji, Youssra |e verfasserin |4 aut | |
| 700 | 1 | |a Barnard, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Benny, Liza |e verfasserin |4 aut | |
| 700 | 1 | |a Buckley, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Cattell, Emma |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Vinton |e verfasserin |4 aut | |
| 700 | 1 | |a Clark, James |e verfasserin |4 aut | |
| 700 | 1 | |a Eastlake, Leonie |e verfasserin |4 aut | |
| 700 | 1 | |a Gerrand, Kate |e verfasserin |4 aut | |
| 700 | 1 | |a Ghafoor, Qamar |e verfasserin |4 aut | |
| 700 | 1 | |a Grumett, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Harper-Wynne, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Kahn, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Alvin J X |e verfasserin |4 aut | |
| 700 | 1 | |a Lydon, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a McKenzie, Hayley |e verfasserin |4 aut | |
| 700 | 1 | |a Panneerselvam, Hari |e verfasserin |4 aut | |
| 700 | 1 | |a Pascoe, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Grisma |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Vijay |e verfasserin |4 aut | |
| 700 | 1 | |a Potter, Vanessa |e verfasserin |4 aut | |
| 700 | 1 | |a Randle, Amelia |e verfasserin |4 aut | |
| 700 | 1 | |a Rigg, Anne S |e verfasserin |4 aut | |
| 700 | 1 | |a Robinson, Tim |e verfasserin |4 aut | |
| 700 | 1 | |a Roylance, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Roques, Tom |e verfasserin |4 aut | |
| 700 | 1 | |a Rozmanowski, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Roux, René L |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Ketan |e verfasserin |4 aut | |
| 700 | 1 | |a Sintler, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Taylor, Harriet |e verfasserin |4 aut | |
| 700 | 1 | |a Tillett, Tania |e verfasserin |4 aut | |
| 700 | 1 | |a Tuthill, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Beggs, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Iveson, Tim |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Siow Ming |e verfasserin |4 aut | |
| 700 | 1 | |a Middleton, Gary |e verfasserin |4 aut | |
| 700 | 1 | |a Middleton, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Protheroe, Andrew S |e verfasserin |4 aut | |
| 700 | 1 | |a Fittall, Matthew W |e verfasserin |4 aut | |
| 700 | 1 | |a Fowler, Tom |e verfasserin |4 aut | |
| 700 | 1 | |a Johnson, Peter |e verfasserin |4 aut | |
| 700 | 0 | |a UK COVID Cancer Programme |e verfasserin |4 aut | |
| 700 | 1 | |a Kinloch, Emma |c Ms |e investigator |4 oth | |
| 700 | 1 | |a Lam, Emily |c Ms |e investigator |4 oth | |
| 700 | 1 | |a Murphy, Gillian |c Ms |e investigator |4 oth | |
| 700 | 1 | |a Rhodes, Malcolm |c Mr |e investigator |4 oth | |
| 700 | 1 | |a Robinson, Kate |c Ms |e investigator |4 oth | |
| 700 | 1 | |a Swarup, Sanskriti |c Ms |e investigator |4 oth | |
| 700 | 1 | |a Bernhardt, Keeley |c Ms |e investigator |4 oth | |
| 700 | 1 | |a Bytyci, Jola |c Ms |e investigator |4 oth | |
| 700 | 1 | |a Ying, Yuxin |c Ms |e investigator |4 oth | |
| 700 | 1 | |a Johal, Sukhmunni |c Ms |e investigator |4 oth | |
| 700 | 1 | |a Sheehan, Remarez |c Mr |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t JAMA oncology |d 2015 |g 9(2023), 2 vom: 01. Feb., Seite 188-196 |w (DE-627)NLM250070588 |x 2374-2445 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2023 |g number:2 |g day:01 |g month:02 |g pages:188-196 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1001/jamaoncol.2022.5974 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2023 |e 2 |b 01 |c 02 |h 188-196 | ||